In pancreatic ductal adenocarcinoma (PDAC) [46], liver [45], breast [47], and colon cancers [46], MCM7 was shown to influence therapeutic response, supporting its promise as a potential therapeutic target. Here, MCM7 is linked to malignant colon neoplasm.